VYNE Therapeutics (VYNE) Stock Forecast, Price Target & Predictions
VYNE Stock Forecast
VYNE Therapeutics stock forecast is as follows: an average price target of $5.75 (represents a 209.14% upside from VYNE’s last price of $1.86) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
VYNE Price Target
The average price target for VYNE Therapeutics (VYNE) is $5.75 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $5.75 to $5.75. This represents a potential 209.14% upside from VYNE's last price of $1.86.
VYNE Analyst Ratings
According to 2 Wall Street analysts, VYNE Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for VYNE stock is 0 'Strong Buy' (0.00%), 2 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
VYNE Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jun 14, 2024 | Joseph Pantginis | H.C. Wainwright | $5.75 | $2.11 | 172.51% | 209.14% |
The latest VYNE Therapeutics stock forecast, released on Jun 14, 2024 by Joseph Pantginis from H.C. Wainwright, set a price target of $5.75, which represents a 172.51% increase from the stock price at the time of the forecast ($2.11), and a 209.14% increase from VYNE last price ($1.86).
VYNE Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $5.75 |
| Last Closing Price | $1.86 | $1.86 | $1.86 |
| Upside/Downside | -100.00% | -100.00% | 209.14% |
In the current month, the average price target of VYNE Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to VYNE Therapeutics's last price of $1.86. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 13, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Aug 15, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Aug 15, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Jun 14, 2024 | H.C. Wainwright | Buy | Buy | Hold |
VYNE Therapeutics's last stock rating was published by H.C. Wainwright on Sep 13, 2024. The company gave VYNE a "Buy" rating, the same as its previous rate.
VYNE Therapeutics Financial Forecast
VYNE Therapeutics Revenue Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | Jun 18 | Mar 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | $76.00K | $114.00K | $135.00K | $99.00K | $6.00K | $167.00K | - | $178.00K | $2.29M | $4.09M | $4.26M | $4.12M | $4.29M | $3.27M | $11.69M | $1.75M | - | - | - | - | - | $10.14M | $497.00K |
| Avg Forecast | $200.00K | $110.00K | $110.00K | $100.00K | $150.00K | $150.00K | $50.00K | $6.29M | $60.00K | $50.00K | $100.00K | $366.67K | $4.02M | $4.76M | $6.35M | $4.77M | $4.71M | $3.31M | $1.59M | $1.57M | $13.64M | $15.09M | $12.40M | $13.21M | $19.70M | $27.20M | $11.36M |
| High Forecast | $200.00K | $110.00K | $110.00K | $100.00K | $150.00K | $150.00K | $50.00K | $7.55M | $60.00K | $50.00K | $100.00K | $366.67K | $4.02M | $4.76M | $6.35M | $4.77M | $4.71M | $3.31M | $1.59M | $1.57M | $16.36M | $18.11M | $14.88M | $15.86M | $23.64M | $32.65M | $13.64M |
| Low Forecast | $200.00K | $110.00K | $110.00K | $100.00K | $150.00K | $150.00K | $50.00K | $5.03M | $60.00K | $50.00K | $100.00K | $366.67K | $4.02M | $4.76M | $6.35M | $4.77M | $4.71M | $3.31M | $1.59M | $1.57M | $10.91M | $12.07M | $9.92M | $10.57M | $15.76M | $21.76M | $9.09M |
| # Analysts | - | 1 | - | - | 1 | - | 13 | 14 | 6 | 6 | 9 | 6 | 7 | 12 | 7 | 16 | 11 | 8 | 8 | 12 | 17 | 20 | 17 | 11 | 16 | 15 | 14 |
| Surprise % | - | - | - | - | 0.51% | 0.76% | 2.70% | 0.02% | 0.10% | 3.34% | - | 0.49% | 0.57% | 0.86% | 0.67% | 0.86% | 0.91% | 0.99% | 7.37% | 1.12% | - | - | - | - | - | 0.37% | 0.04% |
VYNE Therapeutics's average Quarter revenue forecast for Mar 24 based on 0 analysts is $100.00K, with a low forecast of $100.00K, and a high forecast of $100.00K. VYNE's average Quarter revenue forecast represents a 31.58% increase compared to the company's last Quarter revenue of $76.00K (Dec 23).
VYNE Therapeutics EBITDA Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | Jun 18 | Mar 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | 1 | - | - | 1 | - | 13 | 14 | 6 | 6 | 9 | 6 | 7 | 12 | 7 | 16 | 11 | 8 | 8 | 12 | 17 | 20 | 17 | 11 | 16 | 15 | 14 |
| EBITDA | - | - | - | - | $-5.45M | $-6.23M | $-10.32M | $-5.88M | $-7.75M | $-9.08M | - | $-8.65M | $-11.99M | $-17.78M | $-18.82M | $-19.46M | $-22.27M | $-23.42M | $-166.52M | $-39.07M | $-16.68M | $-16.31M | $-18.68M | $-17.58M | $-12.84M | $-8.35M | $-12.65M |
| Avg Forecast | $-200.00K | $-110.00K | $-110.00K | $-37.60M | $-150.00K | $-150.00K | $-50.00K | $-29.72M | $-60.00K | $-17.04M | $-100.00K | $-23.50M | $-18.29M | $-13.47M | $-17.25M | $-21.36M | $-4.71M | $-26.18M | $-215.81M | $-34.42M | $-18.82M | $-20.09M | $-19.48M | $-19.57M | $-18.78M | $-11.60M | $-11.50M |
| High Forecast | $-200.00K | $-110.00K | $-110.00K | $-30.08M | $-150.00K | $-150.00K | $-50.00K | $-23.78M | $-60.00K | $-13.63M | $-100.00K | $-18.80M | $-14.64M | $-10.78M | $-13.80M | $-17.09M | $-4.71M | $-20.94M | $-172.65M | $-27.54M | $-15.06M | $-16.08M | $-15.58M | $-15.65M | $-15.02M | $-9.28M | $-9.20M |
| Low Forecast | $-200.00K | $-110.00K | $-110.00K | $-45.12M | $-150.00K | $-150.00K | $-50.00K | $-35.67M | $-60.00K | $-20.45M | $-100.00K | $-28.19M | $-21.95M | $-16.17M | $-20.70M | $-25.63M | $-4.71M | $-31.41M | $-258.97M | $-41.31M | $-22.59M | $-24.11M | $-23.37M | $-23.48M | $-22.53M | $-13.92M | $-13.80M |
| Surprise % | - | - | - | - | 36.30% | 41.56% | 206.36% | 0.20% | 129.13% | 0.53% | - | 0.37% | 0.66% | 1.32% | 1.09% | 0.91% | 4.73% | 0.89% | 0.77% | 1.13% | 0.89% | 0.81% | 0.96% | 0.90% | 0.68% | 0.72% | 1.10% |
undefined analysts predict VYNE's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than VYNE Therapeutics's previous annual EBITDA (undefined) of $NaN.
VYNE Therapeutics Net Income Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | Jun 18 | Mar 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | 1 | - | - | 1 | - | 13 | 14 | 6 | 6 | 9 | 6 | 7 | 12 | 7 | 16 | 11 | 8 | 8 | 12 | 17 | 20 | 17 | 11 | 16 | 15 | 14 |
| Net Income | - | - | - | - | $-6.19M | $-6.58M | $-10.06M | $-5.62M | $-7.76M | $-9.46M | - | $4.67M | $-11.57M | $-21.29M | $-19.92M | $-20.55M | $-23.18M | $-24.71M | $-167.44M | $-40.23M | $-16.86M | $-16.48M | $-18.87M | $-17.59M | $-12.85M | $-8.35M | $-12.66M |
| Avg Forecast | $-10.86M | $-10.01M | $-8.09M | $-39.70M | $-21.29M | $-32.37M | $-109.87M | $-31.39M | $-137.98M | $-20.40M | $-132.21M | $-24.81M | $-17.46M | $-16.13M | $-18.26M | $-22.55M | $-296.22M | $-27.62M | $-217.00M | $-35.45M | $-18.39M | $-19.42M | $-18.87M | $-18.68M | $-17.61M | $-11.60M | $-11.51M |
| High Forecast | $-10.86M | $-8.76M | $-8.09M | $-31.76M | $-21.29M | $-32.37M | $-109.87M | $-25.11M | $-137.98M | $-16.32M | $-132.21M | $-19.85M | $-13.97M | $-12.90M | $-14.61M | $-18.04M | $-296.22M | $-22.10M | $-173.60M | $-28.36M | $-14.71M | $-15.54M | $-15.10M | $-14.94M | $-14.09M | $-9.28M | $-9.21M |
| Low Forecast | $-10.86M | $-10.84M | $-8.09M | $-47.64M | $-21.29M | $-32.37M | $-109.87M | $-37.66M | $-137.98M | $-24.48M | $-132.21M | $-29.77M | $-20.96M | $-19.35M | $-21.92M | $-27.07M | $-296.22M | $-33.15M | $-260.40M | $-42.54M | $-22.06M | $-23.30M | $-22.65M | $-22.41M | $-21.13M | $-13.92M | $-13.81M |
| Surprise % | - | - | - | - | 0.29% | 0.20% | 0.09% | 0.18% | 0.06% | 0.46% | - | -0.19% | 0.66% | 1.32% | 1.09% | 0.91% | 0.08% | 0.89% | 0.77% | 1.13% | 0.92% | 0.85% | 1.00% | 0.94% | 0.73% | 0.72% | 1.10% |
VYNE Therapeutics's average Quarter net income forecast for Jul 22 is $-132.21M, with a range of $-132.21M to $-132.21M. VYNE's average Quarter net income forecast represents a -2931.14% decrease compared to the company's last Quarter net income of $4.67M (Mar 22).
VYNE Therapeutics SG&A Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | Jun 18 | Mar 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | 1 | - | - | 1 | - | 13 | 14 | 6 | 6 | 9 | 6 | 7 | 12 | 7 | 16 | 11 | 8 | 8 | 12 | 17 | 20 | 17 | 11 | 16 | 15 | 14 |
| SG&A | - | - | - | - | $3.88M | $3.03M | $3.22M | $3.24M | $3.71M | $3.95M | - | $4.42M | $8.20M | $13.83M | $15.84M | $16.62M | $17.90M | $19.77M | $26.46M | $25.41M | $4.80M | $3.76M | $3.75M | $3.36M | $3.04M | $3.09M | $2.70M |
| Avg Forecast | $4.98M | $2.74M | $2.74M | $2.49M | $3.74M | $3.74M | $1.25M | $156.77M | $1.50M | $1.25M | $2.49M | $9.14M | $3.34M | $118.66M | $158.27M | $118.78M | $117.30M | $82.55M | $39.52M | $39.09M | $5.24M | $4.43M | $3.75M | $3.57M | $4.16M | $4.29M | $2.45M |
| High Forecast | $4.98M | $2.74M | $2.74M | $2.49M | $3.74M | $3.74M | $1.25M | $188.13M | $1.50M | $1.25M | $2.49M | $9.14M | $4.01M | $118.66M | $158.27M | $118.78M | $117.30M | $82.55M | $39.52M | $39.09M | $6.29M | $5.32M | $4.50M | $4.29M | $4.99M | $5.15M | $2.94M |
| Low Forecast | $4.98M | $2.74M | $2.74M | $2.49M | $3.74M | $3.74M | $1.25M | $125.42M | $1.50M | $1.25M | $2.49M | $9.14M | $2.67M | $118.66M | $158.27M | $118.78M | $117.30M | $82.55M | $39.52M | $39.09M | $4.19M | $3.54M | $3.00M | $2.86M | $3.33M | $3.44M | $1.96M |
| Surprise % | - | - | - | - | 1.04% | 0.81% | 2.58% | 0.02% | 2.48% | 3.17% | - | 0.48% | 2.45% | 0.12% | 0.10% | 0.14% | 0.15% | 0.24% | 0.67% | 0.65% | 0.92% | 0.85% | 1.00% | 0.94% | 0.73% | 0.72% | 1.10% |
VYNE Therapeutics's average Quarter SG&A projection for Mar 24 is $2.49M, based on 0 Wall Street analysts, with a range of $2.49M to $2.49M. The forecast indicates a -35.85% fall compared to VYNE last annual SG&A of $3.88M (Dec 23).
VYNE Therapeutics EPS Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | Jun 18 | Mar 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | 1 | - | - | 1 | - | 13 | 14 | 6 | 6 | 9 | 6 | 7 | 12 | 7 | 16 | 11 | 8 | 8 | 12 | 17 | 20 | 17 | 11 | 16 | 15 | 14 |
| EPS | - | - | - | - | $-0.60 | $-2.01 | $-3.07 | $-1.73 | $-2.60 | $-2.94 | - | $1.44 | $-3.89 | $-7.36 | $-6.98 | $-7.57 | $-8.54 | $-10.61 | $-86.95 | $-68.14 | $-50.66 | $-49.65 | $-58.35 | $-54.68 | $-40.26 | $-26.28 | $-51.83 |
| Avg Forecast | $-0.26 | $-0.23 | $-0.19 | $-0.24 | $-0.50 | $-0.76 | $-2.58 | $-25.73 | $-3.24 | $-2.82 | $-3.10 | $-2.88 | $-4.46 | $-5.52 | $-6.27 | $-7.92 | $-9.54 | $-11.83 | $-17.40 | $-37.98 | $-54.84 | $-60.62 | $-58.18 | $-0.86 | $-1.22 | $-1.10 | $-0.60 |
| High Forecast | $-0.26 | $-0.21 | $-0.19 | $-0.24 | $-0.50 | $-0.76 | $-2.58 | $-25.73 | $-3.24 | $-2.82 | $-3.10 | $-2.88 | $-4.46 | $-5.52 | $-6.27 | $-7.92 | $-9.54 | $-11.83 | $-17.40 | $-37.98 | $-54.84 | $-60.62 | $-58.18 | $-0.69 | $-0.98 | $-0.88 | $-0.48 |
| Low Forecast | $-0.26 | $-0.25 | $-0.19 | $-0.24 | $-0.50 | $-0.76 | $-2.58 | $-25.73 | $-3.24 | $-2.82 | $-3.10 | $-2.88 | $-4.46 | $-5.52 | $-6.27 | $-7.92 | $-9.54 | $-11.83 | $-17.40 | $-37.98 | $-54.84 | $-60.62 | $-58.18 | $-1.03 | $-1.46 | $-1.32 | $-0.72 |
| Surprise % | - | - | - | - | 1.20% | 2.64% | 1.19% | 0.07% | 0.80% | 1.04% | - | -0.50% | 0.87% | 1.33% | 1.11% | 0.96% | 0.90% | 0.90% | 5.00% | 1.79% | 0.92% | 0.82% | 1.00% | 63.58% | 33.00% | 23.89% | 86.38% |
According to 9 Wall Street analysts, VYNE Therapeutics's projected average Quarter EPS for Jul 22 is $-3.10, with a low estimate of $-3.10 and a high estimate of $-3.10. This represents a -315.63% decrease compared to VYNE previous annual EPS of $1.44 (Mar 22).
VYNE Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| AKTX | Akari Therapeutics | $3.14 | $12.00K | 382065.61% | - |
| FWBI | Entero Therapeutics | $2.96 | $270.00 | 9021.62% | Buy |
| BCEL | Atreca | $0.09 | $4.00 | 4344.44% | Buy |
| KRON | Kronos Bio | $0.92 | $7.63 | 729.35% | Buy |
| LGVN | Longeveron | $2.05 | $10.00 | 387.80% | Buy |
| VYNE | VYNE Therapeutics | $1.86 | $5.75 | 209.14% | Buy |
| GOVX | GeoVax Labs | $2.69 | $8.00 | 197.40% | Buy |
| SABS | SAB Biotherapeutics | $2.56 | $5.67 | 121.48% | Buy |
| CDTX | Cidara Therapeutics | $11.62 | $24.00 | 106.54% | Buy |
| LYRA | Lyra Therapeutics | $0.27 | $0.50 | 85.19% | Hold |
| AXLA | Axcella Health | $4.58 | $6.00 | 31.00% | Buy |
| ZURA | Zura Bio | $4.13 | $5.00 | 21.07% | Buy |
| VCYT | Veracyte | $33.76 | $26.00 | -22.99% | Buy |
VYNE Forecast FAQ
Is VYNE Therapeutics a good buy?
Yes, according to 2 Wall Street analysts, VYNE Therapeutics (VYNE) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 100.00% of VYNE's total ratings.
What is VYNE's price target?
VYNE Therapeutics (VYNE) average price target is $5.75 with a range of $5.75 to $5.75, implying a 209.14% from its last price of $1.86. The data is based on 2 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will VYNE Therapeutics stock go up soon?
According to Wall Street analysts' prediction for VYNE stock, the company can go up by 209.14% (from the last price of $1.86 to the average price target of $5.75), up by 209.14% based on the highest stock price target, and up by 209.14% based on the lowest stock price target.
Can VYNE Therapeutics stock reach $3?
VYNE's average twelve months analyst stock price target of $5.75 supports the claim that VYNE Therapeutics can reach $3 in the near future.
What are VYNE Therapeutics's analysts' financial forecasts?
VYNE's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $520K (high $520K, low $520K), average EBITDA is $-38.018M (high $-30.499M, low $-45.538M), average net income is $-68.661M (high $-59.469M, low $-77.435M), average SG&A $12.96M (high $12.96M, low $12.96M), and average EPS is $-0.92 (high $-0.891, low $-0.94).
Did the VYNE's actual financial results beat the analysts' financial forecasts?
Based on VYNE Therapeutics's last annual report (Dec 2023), the company's revenue was $424K, which missed the average analysts forecast of $6.64M by -93.62%. Apple's EBITDA was $-27.872M, missing the average prediction of $-30.072M by -7.32%. The company's net income was $-28.452M, missing the average estimation of $-195M by -85.40%. Apple's SG&A was $13.38M, missing the average forecast of $165.49M by -91.92%. Lastly, the company's EPS was $-2.77, missing the average prediction of $-29.57 by -90.63%. In terms of the last quarterly report (Dec 2023), VYNE Therapeutics's revenue was $76K, missing the average analysts' forecast of $150K by -49.33%. The company's EBITDA was $-5.445M, beating the average prediction of $-150K by 3530.00%. VYNE Therapeutics's net income was $-6.188M, missing the average estimation of $-21.293M by -70.94%. The company's SG&A was $3.88M, beating the average forecast of $3.74M by 3.93%. Lastly, the company's EPS was $-0.6, beating the average prediction of $-0.5 by 20.00%